We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases / Novasep’s EUR 4 million plant extension for commercial ADC payload manufacturing now commissioned

Novasep’s EUR 4 million plant extension for commercial ADC payload manufacturing now commissioned

15 May 2014

The new Highly Potent API (HPAPI) manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.

Pompey, France, May 15, 2014 - Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that its EUR 4 million (USD 5.5m) investment to expand its highly potent active pharmaceutical ingredients (HPAPI) manufacturing capabilities at its Le Mans facility in France has reached fruition. The plant extension has been fully qualified and is now being used to scale up validation of a commercial ADC (antibody drug conjugate) payload.

HPAPI, the majority of which are used in anti-cancer therapies, must be produced under very strict regulatory conditions to protect any API substance from cross contamination and protect operators from the highly active properties that are intrinsic to these products. Contract Manufacturing Organizations (CMOs) increasingly need to upgrade their facilities with higher containment capabilities. Ensuring supply chain continuity is also important to meet the rising demand in the pharmaceutical ndustry for ADCs.

“We are pleased to see the Le Mans facility commissioned, fully operational and successfully FDA audited,” said Thierry Van Nieuwenhove President of the Synthesis Business unit at Novasep. “There is a high demand from the pharmaceutical industry for CMOs to manufacture potent molecules for use in drugs that improve efficacy and reduce side effects. Novasep has the development and manufacturing capacity, level of specialization and experience to safely address the needs of this market.”

Novasep’s Le Mans plant, notable for producing highly potent cytotoxic pharmaceutical ingredients (APIs) and registered advanced intermediates, recently passed US FDA (Federal Drug Administration) inspection.

The Le Mans production facility combines chemical and purification capabilities to manufacture potent and extremely potent ADC payloads at commercial scale with an OEL (occupational exposure limit) lower than 30 ng/m3 at multi-kg scale per batch.

On top of the classical chemical features in installed confined areas, the production suite can perform cryogenic chemistry at -60 degrees Celsius in hastelloy reactors. The purification suite is equipped with a Prochrom® industrial High-Performance Liquid Chromatography (HPLC) system, which Novasep in Pompey designed and built.

About Novasep
Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life
sciences molecules and fine chemicals. Novasep's unique offering includes process
development services, purification equipment and turnkey processes, contract manufacturing
services and complex active molecules to serve pharmaceutical, biopharmaceutical, fine
chemical, food and functional ingredients as well as bio-sourced chemicals and bio-industries.

Andrew Lloyd & Associates
Carol Leslie
UK and US: +44 1273 675 100
France: +33 1 56 54 07 00

Novasep Icon PDF

Back to full list of events

You can stay on this page and select more documents or you can directly download the brochure(s) you selected
Give us your feedback!